Staging of Lung Cancer

Clinics in Chest Medicine

Volumn 36, Issue 2, 2015, Pages 179-196

  de Groot, Patricia M ^a   Carter, Brett W ^a   Betancourt Cuellar, Sonia L ^a   Erasmus, Jeremy J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Lung cancer; NSCLC; TNM staging

Indexed keywords

FLUORODEOXYGLUCOSE F 18; TUMOR MARKER;

CANCER PROGNOSIS; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; HISTOLOGY; HUMAN; LUNG CANCER; LUNG METASTASIS; LUNG NODULE; LYMPH NODE METASTASIS; NON SMALL CELL LUNG CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIMARY TUMOR; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVIEW; SYNCHRONOUS PRIMARY LUNG CANCER; THORAX RADIOGRAPHY; TREATMENT PLANNING; CARCINOMA, NON-SMALL-CELL LUNG; LUNG NEOPLASMS; POSITRON EMISSION TOMOGRAPHY; PROCEDURES;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; MAGNETIC RESONANCE IMAGING; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84930179586     PISSN: 02725231     EISSN: 15578216     Source Type: Journal    
DOI: 10.1016/j.ccm.2015.02.004     Document Type: Review

References (106)

1. Reck M., Heigener D.F., Mok T., et al. Management of non-small-cell lung cancer: recent developments. Lancet 2013, 382(9893):709-719.
2. Silvestri G.A., Gonzalez A.V., Jantz M.A., et al. Methods for staging non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013, 143(Suppl 5):e211S-e250S.
3. Farjah F., Flum D.R., Ramsey S.D., et al. Multi-modality mediastinal staging for lung cancer among Medicare beneficiaries. JThorac Oncol 2009, 4(3):355-363.
4. Ohno Y., Adachi S., Motoyama A., et al. Multiphase ECG-triggered 3D contrast-enhanced MR angiography: utility for evaluation of hilar and mediastinal invasion of bronchogenic carcinoma. JMagn Reson Imaging 2001, 13(2):215-224.
5. Hollings N., Shaw P. Diagnostic imaging of lung cancer. Eur Respir J 2002, 19(4):722-742.
6. Koyama H., Ohno Y., Seki S., et al. Magnetic resonance imaging for lung cancer. JThorac Imaging 2013, 28(3):138-150.
7. van Tinteren H., Hoekstra O.S., Smit E.F., et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet 2002, 359(9315):1388-1393.
8. Reed C.E., Harpole D.H., Posther K.E., et al. Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable non-small cell lung cancer. JThorac Cardiovasc Surg 2003, 126(6):1943-1951.
9. Antoch G., Stattaus J., Nemat A.T., et al. Non-small cell lung cancer: dual-modality PET/CT in preoperative staging. Radiology 2003, 229(2):526-533.
10. Weder W., Schmid R.A., Bruchhaus H., et al. Detection of extrathoracic metastases by positron emission tomography in lung cancer. Ann Thorac Surg 1998, 66:886-893.
11. Goldstraw P., Crowley J., Chansky K., et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. JThorac Oncol 2007, 2(8):706-714.
12. Shepherd F.A., Crowley J., Van Houtte P., et al. The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. JThorac Oncol 2007, 2(12):1067-1077.
13. Jett J.R., Schild S.E., Kesler K.A., et al. Treatment of small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013, 143(Suppl 5):e400S-e419S.
14. Rami-Porta R., Ball D., Crowley J., et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. JThorac Oncol 2007, 2(7):593-602.
15. Erasmus J.J., Gladish G.W., Broemeling L., et al. Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response. JClin Oncol 2003, 21(13):2574-2582.
16. Wang J., Wu N., Zheng Q.F., et al. Application of the 2007 lung cancer staging system by International Association for the Study of Lung Cancer. Beijing Da Xue Xue Bao 2009, 41(4):442-446. [in Chinese].
17. Ridge C.A., Huang J., Cardoza S., et al. Comparison of multiplanar reformatted CT lung tumor measurements to axial tumor measurement alone: impact on maximal tumor dimension and T stage. AJR Am J Roentgenol 2013, 201(5):959-963.
18. Ohno Y., Koyama H., Dinkel J., et al. Lung cancer. MRI of the Lung 2009, 179-216. Springer-Verlag Berlin, Heidelberg (Germany). H. Kauczor (Ed.).
19. Qi L.P., Zhang X.P., Tang L., et al. Using diffusion-weighted MR imaging for tumor detection in the collapsed lung: a preliminary study. Eur Radiol 2009, 19(2):333-341.
20. Ratto G.B., Piacenza G., Frola C., et al. Chest wall involvement by lung cancer: computed tomographic detection and results of operation. Ann Thorac Surg 1991, 51:182-188.
21. Padovani B., Mouroux J., Seksik L., et al. Chest wall invasion by bronchogenic carcinoma: evaluation with MR imaging. Radiology 1993, 187(1):33-38.
22. Freundlich I.M., Chasen M.H., Varma D.G. Magnetic resonance imaging of pulmonary apical tumors. JThorac Imaging 1996, 11(3):210-222.
23. Bruzzi J.F., Komaki R., Walsh G.L., et al. Imaging of non-small cell lung cancer of the superior sulcus: part 1: anatomy, clinical manifestations, and management. Radiographics 2008, 28(2):551-560. [quiz: 620].
24. Bruzzi J.F., Komaki R., Walsh G.L., et al. Imaging of non-small cell lung cancer of the superior sulcus: part 2: initial staging and assessment of resectability and therapeutic response. Radiographics 2008, 28(2):561-572.
25. Dartevelle P., Macchiarini P. Surgical management of superior sulcus tumors. Oncologist 1999, 4(5):398-407.
26. Bilsky M.H., Vitaz T.W., Boland P.J., et al. Surgical treatment of superior sulcus tumors with spinal and brachial plexus involvement. JNeurosurg 2002, 97(Suppl 3):301-309.
27. Uehara H., Tsutani Y., Okumura S., et al. Prognostic role of positron emission tomography and high-resolution computed tomography in clinical stage IA lung adenocarcinoma. Ann Thorac Surg 2013, 96(6):1958-1965.
28. Mountain C.F., Dresler C.M. Regional lymph node classification for lung cancer staging. Chest 1997, 111:1718-1723.
29. Naruke T., Suemasu K., Ishikawa S. Lymph node mapping and curability at various levels of metastasis in resected lung cancer. JThorac Cardiovasc Surg 1978, 76(6):832-839.
30. Goldstraw P. New staging system: how does it affect our practice?. JClin Oncol 2013, 31(8):984-991.
31. Rusch V.W., Asamura H., Watanabe H., et al. The IASLC lung cancer staging project: a proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer. JThorac Oncol 2009, 4(5):568-577.
32. Watanabe S., Ladas G., Goldstraw P. Inter-observer variability in systematic nodal dissection: comparison of European and Japanese nodal designation. Ann Thorac Surg 2002, 73(1):245-248. [discussion: 248-9].
33. El-Sherief A.H., Lau C.T., Wu C.C., et al. International association for the study of lung Cancer (IASLC) lymph node map: radiologic review with CT illustration. Radiographics 2014, 34(6):1680-1691.
34. Rusch V.W., Crowley J., Giroux D.J., et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the N descriptors in the forthcoming seventh edition of the TNM classification for lung cancer. JThorac Oncol 2007, 2(7):603-612.
35. Prenzel K.L., Monig S.P., Sinning J.M., et al. Lymph node size and metastatic infiltration in non-small cell lung cancer. Chest 2003, 123(2):463-467.
36. Toloza E.M., Harpole L., McCrory D.C. Noninvasive staging of non-small cell lung cancer: a review of the current evidence. Chest 2003, 123(Suppl 1):137S-146S.
37. Herth F.J., Eberhardt R., Krasnik M., et al. Endobronchial ultrasound-guided transbronchial needle aspiration of lymph nodes in the radiologically and positron emission tomography-normal mediastinum in patients with lung cancer. Chest 2008, 133(4):887-891.
38. Veeramachaneni N.K., Battafarano R.J., Meyers B.F., et al. Risk factors for occult nodal metastasis in clinical T1N0 lung cancer: a negative impact on survival. Eur J Cardiothorac Surg 2008, 33(3):466-469.
39. Birim O., Kappetein A.P., Stijnen T., et al. Meta-analysis of positron emission tomographic and computed tomographic imaging in detecting mediastinal lymph node metastases in nonsmall cell lung cancer. Ann Thorac Surg 2005, 79(1):375-382.
40. Bille A., Pelosi E., Skanjeti A., et al. Preoperative intrathoracic lymph node staging in patients with non-small-cell lung cancer: accuracy of integrated positron emission tomography and computed tomography. Eur J Cardiothorac Surg 2009, 36(3):440-445.
41. de Langen A.J., Raijmakers P., Riphagen I., et al. The size of mediastinal lymph nodes and its relation with metastatic involvement: a meta-analysis. Eur J Cardiothorac Surg 2006, 29(1):26-29.
42. Miyasaka Y., Suzuki K., Takamochi K., et al. The maximum standardized uptake value of fluorodeoxyglucose positron emission tomography of the primary tumour is a good predictor of pathological nodal involvement in clinical N0 non-small-cell lung cancer. Eur J Cardiothorac Surg 2013, 44(1):83-87.
43. Park H.K., Jeon K., Koh W.J., et al. Occult nodal metastasis in patients with non-small cell lung cancer at clinical stage IA by PET/CT. Respirology 2010, 15(8):1179-1184.
44. Trister A.D., Pryma D.A., Xanthopoulos E., et al. Prognostic value of primary tumor FDG uptake for occult mediastinal lymph node involvement in clinically N2/N3 node-negative non-small cell lung cancer. Am J Clin Oncol 2014, 37(2):135-139.
45. Maeda R., Isowa N., Onuma H., et al. The maximum standardized 18F-fluorodeoxyglucose uptake on positron emission tomography predicts lymph node metastasis and invasiveness in clinical stage IA non-small cell lung cancer. Interact Cardiovasc Thorac Surg 2009, 9(1):79-82.
46. Lee P.C., Port J.L., Korst R.J., et al. Risk factors for occult mediastinal metastases in clinical stage I non-small cell lung cancer. Ann Thorac Surg 2007, 84(1):177-181.
47. Hellwig D., Groschel A., Graeter T.P., et al. Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2006, 33(1):13-21.
48. Bradley J., Thorstad W.L., Mutic S., et al. Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2004, 59(1):78-86.
49. Perigaud C., Bridji B., Roussel J.C., et al. Prospective preoperative mediastinal lymph node staging by integrated positron emission tomography-computerised tomography in patients with non-small-cell lung cancer. Eur J Cardiothorac Surg 2009, 36(4):731-736.
50. Booth K., Hanna G.G., McGonigle N., et al. The mediastinal staging accuracy of 18F-Fluorodeoxyglycose positron emission tomography/computed tomography in non-small cell lung cancer with variable time intervals to surgery. Ulster Med J 2013, 82(2):75-81.
51. Postmus P.E., Brambilla E., Chansky K., et al. The IASLC Lung Cancer Staging Project: proposals for revision of the M descriptors in the forthcoming (seventh) edition of the TNM classification of lung cancer. JThorac Oncol 2007, 2(8):686-693.
52. Rami-Porta R., Bolejack V., Goldstraw P. The new tumor, node, and metastasis staging system. Semin Respir Crit Care Med 2011, 32(1):44-51.
53. Rivera M.P., Mehta A.C., Wahidi M.M. Establishing the diagnosis of lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013, 143(Suppl 5):e142S-e165S.
54. Erasmus J.J., McAdams H.P., Rossi S.E., et al. FDG PET of pleural effusions in patients with non-small cell lung cancer. AJR Am J Roentgenol 2000, 175(1):245-249.
55. Schaffler G.J., Wolf G., Schoellnast H., et al. Non-small cell lung cancer: evaluation of pleural abnormalities on CT scans with 18F FDG PET. Radiology 2004, 231(3):858-865.
56. Detterbeck F.C., Postmus P.E., Tanoue L.T. The stage classification of lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013, 143(Suppl 5):e191S-e210S.
57. Gould M.K., Donington J., Lynch W.R., et al. Evaluation of individuals with pulmonary nodules: when is it lung cancer? Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013, 143(Suppl 5):e93S-e120S.
58. American Joint Committee on Cancer AJCC Cancer staging manual 2009, Springer, New York. 7th edition.
59. Viney R.C., Boyer M.J., King M.T., et al. Randomized controlled trial of the role of positron emission tomography in the management of stage I and II non-small-cell lung cancer. JClin Oncol 2004, 22(12):2357-2362.
60. MacManus M.P., Hicks R.J., Matthews J.P., et al. High rate of detection of unsuspected distant metastases by PET in apparent stage III non-small-cell lung cancer: implications for radical radiation therapy. Int J Radiat Oncol Biol Phys 2001, 50(2):287-293.
61. Min J.W., Um S.W., Yim J.J., et al. The role of whole-body FDG PET/CT, Tc 99m MDP bone scintigraphy, and serum alkaline phosphatase in detecting bone metastasis in patients with newly diagnosed lung cancer. JKorean Med Sci 2009, 24(2):275-280.
62. 18FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with lung cancer. Eur J Radiol 2012, 81(5):1007-1015.
63. Liu N., Ma L., Zhou W., et al. Bone metastasis in patients with non-small cell lung cancer: the diagnostic role of F-18 FDG PET/CT. Eur J Radiol 2010, 74(1):231-235.
64. Ak I., Sivrikoz M.C., Entok E., et al. Discordant findings in patients with non-small-cell lung cancer: absolutely normal bone scans versus disseminated bone metastases on positron-emission tomography/computed tomography. Eur J Cardiothorac Surg 2010, 37(4):792-796.
65. Oliver T.W., Bernardino M.E., Miller J.I., et al. Isolated adrenal masses in nonsmall-cell bronchogenic carcinoma. Radiology 1984, 153(1):217-218.
66. Sahdev A., Reznek R.H. The indeterminate adrenal mass in patients with cancer. Cancer Imaging 2007, 7(Spec No A):S100-S109.
67. Mayo-Smith W.W., Boland G.W., Noto R.B., et al. State-of-the-art adrenal imaging. Radiographics 2001, 21(4):995-1012.
68. Boland G.W., Lee M.J., Gazelle G.S., et al. Characterization of adrenal masses using unenhanced CT: an analysis of the CT literature. AJR Am J Roentgenol 1998, 171:201-204.
69. Pena C.S., Boland G.W., Hahn P.F., et al. Characterization of indeterminate (lipid-poor) adrenal masses: use of washout characteristics at contrast-enhanced CT. Radiology 2000, 217(3):798-802.
70. Boland G.W., Hahn P.F., Pena C., et al. Adrenal masses: characterization with delayed contrast-enhanced CT. Radiology 1997, 202(3):693-696.
71. Boland G.W., Lee M.J. Magnetic resonance imaging of the adrenal gland. Crit Rev Diagn Imaging 1995, 36:115-174.
72. Outwater E.K., Siegelman E.S., Huang A.B., et al. Adrenal masses: correlation between CT attenuation value and chemical shift ratio at MR imaging with in-phase and opposed-phase sequences. Radiology 1996, 200(3):749-752.
73. Schwartz L.H., Ginsberg M.S., Burt M.E., et al. MRI as an alternative to CT-guided biopsy of adrenal masses in patients with lung cancer. Ann Thorac Surg 1998, 65(1):193-197.
74. Boland G.W., Dwamena B.A., Jagtiani Sangwaiya M., et al. Characterization of adrenal masses by using FDG PET: a systematic review and meta-analysis of diagnostic test performance. Radiology 2011, 259(1):117-126.
75. Hooper R.G., Tenholder M.F., Underwood G.H., et al. Computed tomographic scanning of the brain in initial staging of bronchogenic carcinoma. Chest 1984, 85(6):774-776.
76. Mintz B.J., Tuhrim S., Alexander S., et al. Intracranial metastases in the initial staging of bronchogenic carcinoma. Chest 1984, 86(6):850-853.
77. Posther K.E., McCall L.M., Harpole D.H., et al. Yield of brain 18F-FDG PET in evaluating patients with potentially operable non-small cell lung cancer. JNucl Med 2006, 47(10):1607-1611.
78. Ettinger D.S., Akerley W., Bepler G., et al. Non-small cell lung cancer. JNatl Compr Canc Netw 2010, 8(7):740-801.
79. Earnest F.T., Ryu J.H., Miller G.M., et al. Suspected non-small cell lung cancer: incidence of occult brain and skeletal metastases and effectiveness of imaging for detection-pilot study. Radiology 1999, 211(1):137-145.
80. Yokoi K., Kamiya N., Matsuguma H., et al. Detection of brain metastasis in potentially operable non-small cell lung cancer. A comparison of CT and MRI. Chest 1999, 115:714-719.
81. Robnett T.J., Machtay M., Stevenson J.P., et al. Factors affecting the risk of brain metastases after definitive chemoradiation for locally advanced non-small-cell lung carcinoma. JClin Oncol 2001, 19(5):1344-1349.
82. Lardinois D., Weder W., Roudas M., et al. Etiology of solitary extrapulmonary positron emission tomography and computed tomography findings in patients with lung cancer. JClin Oncol 2005, 23(28):6846-6853.
83. De Leyn P., Moons J., Vansteenkiste J., et al. Survival after resection of synchronous bilateral lung cancer. Eur J Cardiothorac Surg 2008, 34(6):1215-1222.
84. Boiselle P.M., Erasmus J.J., Ko J.P., et al. Expert opinion: lung cancer staging. JThorac Imaging 2011, 26(2):85.
85. Finley D.J., Yoshizawa A., Travis W., et al. Predictors of outcomes after surgical treatment of synchronous primary lung cancers. JThorac Oncol 2010, 5(2):197-205.
86. Martini N., Melamed M.R. Multiple primary lung cancers. JThorac Cardiovasc Surg 1975, 70(4):606-612.
87. Okada M., Tsubota N., Yoshimura M., et al. How should interlobar pleural invasion be classified? Prognosis of resected T3 non-small cell lung cancer. Ann Thorac Surg 1999, 68(6):2049-2052.
88. Miura H., Taira O., Uchida O., et al. Invasion beyond interlobar pleura in non-small cell lung cancer. Chest 1998, 114(5):1301-1304.
89. Joshi V., McShane J., Page R., et al. Clinical upstaging of non-small cell lung cancer that extends across the fissure: implications for non-small cell lung cancer staging. Ann Thorac Surg 2011, 91(2):350-353.
90. Haam S.J., Park I.K., Paik H.C., et al. T-stage of non-small cell lung cancer directly invading an adjacent lobe. Eur J Cardiothorac Surg 2012, 42(5):807-810. [discussion: 810-1].
91. Borczuk A.C., Qian F., Kazeros A., et al. Invasive size is an independent predictor of survival in pulmonary adenocarcinoma. Am J Surg Pathol 2009, 33(3):462-469.
92. Sakao Y., Miyamoto H., Sakuraba M., et al. Prognostic significance of a histologic subtype in small adenocarcinoma of the lung: the impact of nonbronchioloalveolar carcinoma components. Ann Thorac Surg 2007, 83(1):209-214.
93. Ravanelli M., Farina D., Morassi M., et al. Texture analysis of advanced non-small cell lung cancer (NSCLC) on contrast-enhanced computed tomography: prediction of the response to the first-line chemotherapy. Eur Radiol 2013, 23(12):3450-3455.
94. Davnall F., Yip C.S., Ljungqvist G., et al. Assessment of tumor heterogeneity: an emerging imaging tool for clinical practice?. Insights Imaging 2012, 3(6):573-589.
95. Lambin P., Rios-Velazquez E., Leijenaar R., et al. Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer 2012, 48(4):441-446.
96. Ganeshan B., Abaleke S., Young R.C., et al. Texture analysis of non-small cell lung cancer on unenhanced computed tomography: initial evidence for a relationship with tumour glucose metabolism and stage. Cancer Imaging 2010, 10:137-143.
97. Balagurunathan Y., Kumar V., Gu Y., et al. Test-retest reproducibility analysis of lung CT image features. JDigit Imaging 2014, 27(6):805-823.
98. Kumar V., Gu Y., Basu S., et al. Radiomics: the process and the challenges. Magn Reson Imaging 2012, 30(9):1234-1248.
99. Bayanati H., E Thornhill R., Souza C.A., et al. Quantitative CT texture and shape analysis: can it differentiate benign and malignant mediastinal lymph nodes in patients with primary lung cancer?. Eur Radiol 2014, 25(2):480-487.
100. Sakai S., Murayama S., Murakami J., et al. Bronchogenic carcinoma invasion of the chest wall: evaluation with dynamic cine MRI during breathing. JComput Assist Tomogr 1997, 21:595-600.
101. Ohno Y., Koyama H., Nogami M., et al. STIR turbo SE MR imaging vs coregistered FDG-PET/CT: quantitative and qualitative assessment of N-stage in non-small-cell lung cancer patients. JMagn Reson Imaging 2007, 26(4):1071-1080.
102. Ohno Y., Hatabu H., Takenaka D., et al. Metastases in mediastinal and hilar lymph nodes in patients with non-small cell lung cancer: quantitative and qualitative assessment with STIR turbo spin-echo MR imaging. Radiology 2004, 231(3):872-879.
103. Yi C.A., Shin K.M., Lee K.S., et al. Non-small cell lung cancer staging: efficacy comparison of integrated PET/CT versus 3.0-T whole-body MR imaging. Radiology 2008, 248(2):632-642.
104. Nomori H., Mori T., Ikeda K., et al. Diffusion-weighted magnetic resonance imaging can be used in place of positron emission tomography for N staging of non-small cell lung cancer with fewer false-positive results. JThorac Cardiovasc Surg 2008, 135(4):816-822.
105. Ohno Y., Koyama H., Onishi Y., et al. Non-small cell lung cancer: whole-body MR examination for M-stage assessment-utility for whole-body diffusion-weighted imaging compared with integrated FDG PET/CT. Radiology 2008, 248(2):643-654.
106. Cogen A., Dockx Y., Cheung K.J., et al. TNM-classification for lung cancer: from the 7th to the 8th edition. Acta Chir Belg 2011, 111(6):389-392.